Expert Interview
Understanding the Advances and Innovations in Diagnostics for Early Detection of Alzheimer's Disease.
Ticker(s): LLY-WD, BIIB, ESALFInterview with a knowledgeable Alzheimer's Disease KOL and/or PI with in-depth knowledge of the current diagnostic strategies being undertaken by companies such as Eli Lilly, Biogen, and Eisai for early AD diagnosis.
What activities are you most interested in that companies are undertaking to address early Alzheimer’s diagnosis gaps across the clinical care pathway?
Added By: pharmaadvisorWhat are your early perceptions of emerging Alzheimer’s Disease Diagnostic Strategies, including Blood-based Biomarkers (BBB) and Elecsys Amyloid Plasma Panel (EAPP) programs?
Added By: pharmaadvisorWhat are your opinions on using BBB and EAPP as the potential foundation for early diagnosis of AD? What are some emerging challenges that you are seeing? Conversely, what are emerging research activities that are sending potential positive signals?
Added By: pharmaadvisorWhat current or planned blood-based biomarker test activities are you most interested in observing and learning the results from?
Added By: pharmaadvisorFor companies with AD therapy programs and diagnostic R&D programs, do you believe companies will use BBB tests to drive uptake of their relative AD therapy?
Added By: pharmaadvisorHow do you think the EAPP research programs progressing? What could potentially accelerate or decelerate R&D activities with these programs?
Added By: pharmaadvisorSome vendors are very optimistic and have publicly stated that blood biomarkers will be used in actual clinical practice from around 2026. What are your thoughts on the likelihood of this timeline? What would need to happen with current BBB studies for this timeline to be accurate?
Added By: pharmaadvisorAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
